ADAM17 and neoplasm: Upon validation, the targeting of ADAM17 may be exploited to prevent tumor metastasis, while the enhanced apoptotic response of T-cells lacking ADAM17 could be facilitated to reduce the quantity of aberrant T-cells in leukemia, autoimmunity and inflammatory diseases.